Linked Life Data

10192299

Source:http://linkedlifedata.com/resource/pubmed/id/10192299

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1999-7-7
pubmed:abstractText
Activation of peripheral blood mononuclear cells (PBMC) with IL-2 generates lymphokine-activated killer (LAK) cells that show a broad target cell range. In adoptive immunotherapy using in vitro-generated LAK cells, the intensity and specificity of their cytotoxic activity affect the prognosis of cancer patients. The present study was designed to examine the tumor-specific spectrum of T lymphocytes generated from the PBMC of patients with recurrent glioblastoma by in vitro propagation with IL-2 plus either soluble or solid-phase anti-CD3 monoclonal antibody (MAb) in short-term or long-term cultures. Both short-term and long-term culturing with solid-phase anti-CD3 MAb plus IL-2 yielded broad-reactivity CD8+ alphabetaT and gammadeltaT lymphocytes, both of which were non-MHC restricted, as shown by the fact that they were able to lyse autologous glioblastoma cells, MHC class I+II- allogeneic glioblastoma cells, and MHC class I-II-NK-sensitive K562 target cells. More importantly, these cells from patients failed to lyse fresh autologous PBMC. These results demonstrate that cells generated using this approach are non-MHC-restricted LAK cells and exhibit marked tumor specificity. In contrast, incubation with soluble anti-CD3 MAb generated T lymphocytes that after long-term culture, were either CD4+ or CD8+. These caused significant lysis of both allogeneic and autologous glioblastoma target cells, the extent of lysis being greater than that using cells produced by culturing with the solid-phase MAb. However, both the CD4+ and CD8+ cells also caused greater lysis of autologous normal PBMC, indicating that cells generated using this approach may cause significant adverse reactions in cancer patients if used for immunotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1061-6128
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
29-37
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed-meshheading:10192299-Adolescent, pubmed-meshheading:10192299-Adult, pubmed-meshheading:10192299-Antibodies, Monoclonal, pubmed-meshheading:10192299-Antigens, CD3, pubmed-meshheading:10192299-Antigens, Neoplasm, pubmed-meshheading:10192299-Cells, Cultured, pubmed-meshheading:10192299-Child, pubmed-meshheading:10192299-Coculture Techniques, pubmed-meshheading:10192299-Cytotoxicity, Immunologic, pubmed-meshheading:10192299-Flow Cytometry, pubmed-meshheading:10192299-Glioblastoma, pubmed-meshheading:10192299-Histocompatibility Antigens Class I, pubmed-meshheading:10192299-Histocompatibility Antigens Class II, pubmed-meshheading:10192299-Humans, pubmed-meshheading:10192299-Interleukin-2, pubmed-meshheading:10192299-Killer Cells, Lymphokine-Activated, pubmed-meshheading:10192299-Leukocytes, Mononuclear, pubmed-meshheading:10192299-Solubility, pubmed-meshheading:10192299-T-Lymphocytes, pubmed-meshheading:10192299-Tumor Cells, Cultured
pubmed:year
1999
pubmed:articleTitle
Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients.
pubmed:affiliation
RIKEN Cell Bank, the Institute of Physical and Chemical Research, Tsukuba, Japan.
pubmed:publicationType
Journal Article